October 27, 2025

Lower GI mistakes: Postop Crohn's, vaccine gaps, colonoscopy errors

There is no routine colonoscopy. Focus on the basics to reduce the impact of inevitable mistakes, done reliably every time.

Conexiant

October 23, 2025

Nutritional IBD screening tools ranked

Single-center cohort finds MIRT most sensitive at predicting malnutrition or low Fat-Free Mass Index within six months in patients in remission with IBD; SaskIBD-NR shows the highest accuracy for GLIM-defined malnutrition and for low Fat-Free Mass Index.

Conexiant

October 14, 2025

Do quadruple therapies beat triple for H. pylori?

Concomitant and bismuth quadruple regimens provided substantially higher eradication rates than triple therapy without an adherence penalty.

Conexiant

October 07, 2025

Open vs robotic liver resections, study results

Complication rates and hospital stays were analyzed across both surgical groups.

Conexiant

October 07, 2025

Global IBD trial experts agree on steroid standards

Global IBD experts issued new guidance on how steroids should be managed in clinical trial settings.

Conexiant

April 26, 2024

Adding Immunotherapy-Based Combo to TACE May Improve PFS in HCC

The addition of durvalumab and bevacizumab to transarterial chemoembolization may improve progression-free survival in unresectable hepatocellular carcinoma.

Conexiant

June 01, 2024

GLP-1 RAs May Cut Pancreatitis Risk

Study finds GLP-1 receptor agonists may reduce risk for acute pancreatitis recurrence.

Conexiant

May 02, 2024

AACR 2024: Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.

Conexiant

November 19, 2024

Wide Variation in SGLT2i Use Across U.S. Hospitals

Study reveals hospital variation in SGLT2i prescriptions, with only 11 of 518 hospitals (2.1%) achieving ≥50% prescription rates while 232 hospitals (44.8%) prescribed to fewer than 10% of eligible heart failure patients, highlighting an implementation gap in evidence-based therapy.

Conexiant